Zydus Lifesciences Climbs on Bioeq Tie-Up for US Biosimilar Rollout

shares edged up 0.24% to Rs 930.35 in early trade, fueled by a new tie-up with Swiss firm Bioeq AG for commercializing NUFYMCO, an interchangeable biosimilar to Lucentis (ranibizumab). Zydus's UAE subsidiary will handle U.S. marketing and sales, while Bioeq manages development, manufacturing, and supply. The USFDA approved NUFYMCO's BLA on December 18, targeting eye conditions like macular degeneration. This deal strengthens Zydus's biosimilars push in the $100B+ U.S. market, with analysts eyeing revenue upside from affordable alternatives post-patent expiry. Launch details pending, but the accord signals growth in high-margin specialties.